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Abstract
Objective: The aim of this study was to examine zolpidem (ZLP) orally disintegrating tablets (ODTs) from different formulations in order to 
characterize their physicochemical properties and thus, provide the necessary prescribing and dispensing information on those preparations.
Methods: Five 5-mg-ZLP ODTs from five different formulations were used in this study. These tablets were subjected to weight and content 
uniformity tests as indicators of quality. In addition, they were subjected to dissolution, wetting time, hardness, and disintegration tests.
Results: The content uniformity test ensured that preparations contained a uniform quantity of the active ingredient. The weight of each 
preparation was the same as that listed on the package insert. In the dissolution test, all the preparations had dissolved by at least 85% after 
15 min. The hardness test showed that, on average, all the preparations had a hardness of at least 30 N. Results of the wetting time and 
disintegration tests indicated that the five preparations have different mechanisms of disintegration.
Conclusion: Our results revealed differences in the physicochemical properties between the five formulations. We concluded from this study 
that formulation differences could affect the disintegration, dissolution, and absorption of ODTs. In order to provide better medical care for each 
individual patient, it is necessary for the pharmacist to pursue information regarding the pharmaceutical properties of medications.
Keywords: Orally Disintegrating Tablets; Physicochemical Properties; Disintegration; Zolpidem
Introduction
Over the past few years, aging of the Japanese population has 
become associated with psychological problems like depression, stress, 
and insomnia [1,2]. Insomnia might be the result of a certain lifestyle, 
environmental conditions, or a mental/physical illness. It might also occur 
as an adverse reaction to a medication. Usually, insomnia is not caused by 
a single factor or disease but by several overlapping factors. Insomnia is 
common among the elderly, but recently, its prevalence has been rising 
among young people too.
A wide range of brand-name and generic drugs are prescribed to 
treat insomnia. A generic contains the same amount of the active 
pharmaceutical ingredient (API) as a brand-name drug. If the Ministry of 
Health, Labour, and Welfare certifies a generic as having the same efficacy 
and action as a brand-name drug, it permits the manufacture and sale 
of this generic. Generally, a generic uses the same API as a brand-name 
drug, making it less expensive to develop (since the API has already been 
identified) and thus less expensive in the market. In other words, the spread 
of generics is believed to reduce medical expenses borne by patients and 
curb government expenditures on medical insurance without lowering 
the quality of medical care. However, in 2015, generics accounted for 
only 56.2% of the pharmaceuticals in Japan, and this is a low percentage 
compared to that in foreign countries [3,4]. One of the reasons for this 
might be the concern of medical personnel about the quality of generics 
and the consistent supply of information on those drugs. In light of these 
circumstances, the Ministry of Health, Labour, and Welfare has devised a 
road map to promote the use of generics.
Conventional oral dosage forms require attention when taken by 
patients who find difficulty in swallowing, like the elderly, to avoid 
aspiration. In addition, for water deprivation patients due to disease, it 
is necessary to take into consideration the amount of water used when 
taking. To address these problems, a new dosage form known as orally 
disintegrating tablets (ODTs) has been developed. This dosage form 
consists of tablets that rapidly disintegrate and dissolve in the saliva and 
are thus easy to swallow without the need for water [5]. In addition, 
patients suffering from dysphagia, motion sickness, repeated emesis, or a 
mental disorder prefer ODTs since they cannot swallow large quantities of 
water [6]. Moreover, it is a suitable dosage form for drugs that are readily 
absorbed via the oral mucosa or have immediate pharmacological action. 
ODTs are classified into three types based on their method of formulation: 
Rapidly disintegrating tablets [7], molded tablets [8], and typical ODTs 
[9]. These three different types differ in the types of disintegrants, types 
of additives, and methods of manufacture, which presumably affects the 
tablets’ disintegration.
Benzodiazepines were considered the treatment of choice for 
insomnia for several years until the advent of newer benzodiazepine-
like drugs termed non benzodiazepines like zolpidem. Zolpidem 
(ZLP) is an imidazopyridine compound that enhances GABAA 
receptor function by binding to the omega (ω)-1 receptor subtype. 
ZLP is widely used in clinical practice because it exerts only a weak 
effect on the ω-2 receptor, which is responsible for muscle relaxation, 
and because patients are less likely to develop tolerance or dependence 
upon ZLP usage even when it is repeatedly administered [10]. 
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Zolpidem is classified as BCS Class I. In Japan, only five companies 
sell generic forms of ZLP ODTs that are evaluated in accordance 
with the guidelines for Bioequivalence Testing of Generic Drugs. 
Since ZLP ODTs can be taken without water, the tablets can be taken 
immediately before bed time. However, different ZLP ODTs contain 
different additives that would presumably result in differences in 
their disintegration time and solubility. It is important to examine 
the characteristics of ZLP ODTs from different formulations in order 
to provide suitable prescribing and dispensing information on those 
preparations. However, the characteristics of different ZLP ODTs have not 
yet been examined.
Therefore, in the current study, we examined ZLP ODTs from five 
different formulations, and checked the tablet shape, weight uniformity, 
and content uniformity as indicators of quality. In addition, we subjected 
the ODTs to a dissolution test, wetting time test, hardness test, and 
disintegration test in order to evaluate the characteristics of the five 
preparations.
Materials and Methods
Materials
ZLP tartrate ODTs (5 mg) from five different formulations were used in 
the present study. The used formulations were: A: Sawai Pharmaceutical 
Co., Ltd., B: Kobayashi Kako Co., Ltd., C: TOWA PHARMACEUTICAL 
Co., Ltd., D: ELMED EISAI Co., Ltd., E: Nichi-Iko Pharmaceutical Co., 
Ltd. ZLP crystals were donated from Sawai Pharmaceutical Co., Ltd. 
Other reagents were of special commercial grade (Wako Pure Chemical 
Industries Co., Ltd.) (Table 1).
Methods
Examination of the appearance: The diameter and thickness of the 
ODTs were measured using a digital vernier caliper (Shinwa Rules Co., 
Ltd.).
Weight uniformity test: All formulations were subjected to a 
uniformity-of-weight test. Weights were measured using an electronic 
balance (GH-252, A&D Co., Ltd.).
Content uniformity test: A content uniformity test was conducted 
in accordance with the 17th edition of the Japanese Pharmacopoeia (JP). 
A sample solution was prepared using ODTs of each formulation and a 
standard solution was prepared using a standard sample of ZLP tartrate. 
High-performance liquid chromatography (HPLC) was used to calculate 
the ZLP tartrate content in proportion to the indicated amount of ZLP 
tartrate in the formulation. Content was ascertained by determining the 
acceptance value as described in the 17th edition of the JP. According to 
the JP, the acceptance value should be 15% or lower, i.e., if the acceptance 
value of a certain formulation does not exceed 15%, this formulation 
complies with the JP.
HPLC analysis: HPLC was performed in accordance with a dissolution 
test for ZLP tartrate tablets specified in the first section of the JP using a 
high-performance liquid chromatograph (HPLC, SPD-20A SHIMADZU 
Corp.). Assay conditions were as follows: Inertsil® ODS-3 column (4×150 
mm, 5 μm); a column temperature of 35°C; a mobile phase consisting 
of a mixture of phosphoric acid, methanol, and acetonitrile (11:5:4); a 
detection wavelength of 254 nm; and a sample injection volume of 40 
µL. ZLP tartrate retention time was set so that the flow rate would be 1.7 
mL/min. The quantitation and detection limits (QL and DL) achieved 
were 0.0000022 mg/mL and 0.00000072 mg/mL, respectively. A standard 
curve was prepared using concentrations of 0.006306, 0.012613, 0.025225, 
0.0509, 0.1018, and 0.2036 mg/mL.
Dissolution test: A dissolution test was conducted in accordance 
with the paddle method in the 17th edition of the JP and the guidelines 
for Bioequivalence Testing of Generic Drugs [11]. The dissolution test 
was performed using a dissolution apparatus (NTR-593, Toyama Sangyo 
Co., Ltd.) at a temperature of 37 ± 0.5°C, stirred at 50 rpm in 900 mL 
of distilled water or artificial saliva [12-14] (Artificial saliva composition: 
component’s concentration (g/L), pH 4.8, 0.4 g NaCl, 0.4 g KCl, 0.795 
g CaCl2.2H2O, 0.78 g NaH2PO4.2H2O, 0.005 g Na2S.9H2O, and 1.0 g 
CO(NH2)2 (Urea) in 1000 mL). Ten milliliters of each sample solution 
were collected after 0, 5, 10, 15, and 30 min. Regarding distilled water, 
the sample solution was filtered through a 0.45-µm membrane ﬁlter. 
Then, 5 mL of the ﬁltered sample was diluted to 25 mL with 20 mL of 
methanol to serve as the sample solution. The content in each sample 
solution was determined using UV-Vis spectrophotometers (UV-2500PC, 
SHIMADZU Corp.).
Detection wavelengths of 246 and 238.5 nm were used for distilled 
water and artificial saliva, respectively.
Wetting time test [15]: This experiment mimics the action of saliva in 
contact with ODTs. A Whatman filter paper disk folded once diametrically 
was placed in a 90-mm-petri dish and immersed in 10 mL distilled water 
or artificial saliva. The tablet was carefully placed on the filter paper over 
the dividing line (t=0) and the time for complete wetting was measured. 
Hardness test: The hardness of each formulation was measured in the 
direction of the diameter using a Monsanto tablet hardness tester (Minato 
Medical Co., Ltd.).
Disintegration test: In order to measure the disintegration time for each 
formulation, the disintegration test was performed using a disintegration 
tester (ODT-101, Toyama Sangyo Co., Ltd.) [16]. This apparatus allows 
OD-
tablets Product company OD-tablets’ additive
A Sawai Pharmaceutical Co. ,Ltd.
Microcrystalline cellulose, Magnesium 
Oxide, Red Ferric Oxide, Sucralose, 
Magnesium Stearate, Vanillin, 
Hydroxypropylcellulose, D-mannitol, 
Magnesium Aluminometasilicate, 
Flavor
B Kobayashi Kako Co., Ltd.
D-Mannitol, Microcrystalline 
Cellulose, Low Substituted 
Hydroxypropylcellulose, Precipitated 
Calcium Carbonate, Tartaric Acid, 
Magnesium Hydroxide, Sucralose, 
Yellow Ferric Oxide, Red Ferric Oxide, 
Flavor, Magnesium Stearate
C
TOWA 
PHARMACEUTICAL 
Co., Ltd.
D-Mannitol, Talc, Yellow Ferric 
Oxide, l- Menthol, Aspartame (L- 
Phenylalanine Compound), Light 
Anhydrous Silicic Acid, Magnesium 
Stearate, Flavor, Other three 
components
D ELMED EISAI Co., Ltd.
Yellow Ferric Oxide, Microcrystalline 
Cellulose, Flavor,  Red Ferric Oxide, 
Tartaric Acid, Magnesium Hydroxide, 
Sucralose, Magnesium Stearate, 
Precipitated Calcium Carbonate, Low 
Substituted Hydroxypropylcellulose, 
D-  Mannitol
E
Nichi-Iko 
Pharmaceutical Co., 
Ltd.
D- Mannitol, Cellulose, Magnesium 
Oxide, Hydroxypropylcellulose, 
Aspartame (L- Phenylalanine 
Compound), Yellow Ferric Oxide, Red 
Ferric Oxide, Magnesium Stearate, 
Flavor
Table 1: List of additives in ODTs
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automatic adjustment of the level of the test medium. A 20-g-ODT sample 
was placed on a stainless-steel porous plate at 37 ± 0.5°Cand stirred at 50 
rpm in 900 mL of distilled water. 
Statistical analysis: Results are presented as the mean  ±  standard 
deviation. Statistical significance was evaluated by Tukey-Kramer test.
Results and Discussion
Examination of the appearance
The diameters and shapes of the five types of tablets were examined 
(Table 2). Preparation A had a diameter of6.52 ± 0.02 mm, preparation 
B had a diameter of 6.59 ± 0.03 mm, preparation C had a diameter of 
7.13 ± 0.03 mm, preparation D had a diameter of 6.58 ± 0.01 mm, and 
preparation E had a diameter of 6.57 ± 0.04 mm. Preparation A had a 
thickness of 2.65 ± 0.25 mm, preparation B had a thickness of 2.74 ± 0.01 
mm, preparation C had a thickness of 3.42 ± 0.02 mm, preparation D had 
a thickness of 2.75 ± 0.02 mm, and preparation E had a thickness of 2.57 
± 0.02 mm. All preparations were scored on one side. 
Weight uniformity test
Preparation A had an average weight of 90.3 ± 0.5 mg, preparation B 
had an average weight of 96.1 ± 0.5 mg, preparation C had an average 
weight of 137.1 ± 0.5 mg, preparation D had an average weight of 96.1 ± 
0.5 mg, and preparation E had an average weight of 90.6 ± 0.7 mg (Table 2). 
The weight of each preparation was the same as that listed on the package 
insert. 
Content uniformity test
This test is done to ensure that all preparations within a batch contain 
equal quantities of the API. Preparation A had an average content of 
103.3 ± 2.7 mg, preparation B had an average content of 102.9 ± 2.0 mg, 
preparation C had an average content of 101.7 ± 3.1 mg, preparation 
D had an average content of 101.7 ± 3.1 mg, and preparation E had an 
average content of 102.36 ± 1.6 mg (Table 2). The ZLP content in all the 
preparations was about 100%. Preparation A had an acceptance value of 
9.7%, preparation B had an acceptance value of 7.8%, preparation C had 
an acceptance value of 9.0%, preparation D had an acceptance value of 
6.1%, and preparation E had an acceptance value of 6.1%. All preparations 
had acceptance value slower than 15%, thus, according to the JP, all the 
preparations passed. These results showed that the API content was 
equivalent in all the preparations. 
Dissolution test
A dissolution test was conducted to determine the bioequivalence of 
the preparations. Results of the dissolution test conducted in purified 
water are shown in Figure 1.The results show that after 15 min, all the 
preparations had dissolved by at least 85%. After 5 min, preparations A, 
B, D, and E had dissolved by 80%, and only preparation C had dissolved 
by 70%, i.e., preparation C dissolved at a significantly lower rate than the 
other preparations. The dissolution test was repeated with artificial saliva 
instead of purified water in order to determine whether saliva would help 
the disintegration of ODTs. Results of the dissolution test conducted in 
artificial saliva are shown in Figure 2. The results show that after 15 min, 
all the preparations had dissolved by at least 85%. However, unlike the 
purified water test, all the preparations in this test had dissolved by about 
90% after 5 min. Only preparation C had dissolved to a significantly lower 
extent than the other preparations after 15 and 30 min. Both preparations 
A and E contained approximately 90 mg of hydroxypropyl cellulose (HPC) 
as an additive, and both preparations B and D contained approximately 
96 mg of low-substituted hydroxyl propyl cellulose (L-HPC), i.e., 
preparations A and E contained the same additive and preparations B 
and D contained the same additive and thus, each set of preparations is 
predicted to have similar characteristics. Based on the current findings, 
there were differences in additives such as binders, disintegrants, and 
solubilizers between the preparations, which resulted in certain tablets 
dissolving more readily than others. This explains the differences in the 
dissolution profiles between the preparations. 
Wetting time test
The dissolution test results showed that only preparation C had a 
different dissolution profile than the other preparations. Thus, we can 
conclude that preparation C presumably disintegrates in a different 
manner, for example, water may enter it in a different manner. Attention 
was focused on this difference, so a wetting time (water absorption) test 
was conducted. Results of this test showed that preparation A absorbed 
purified water in 45.8 ± 4.7 s, preparation B absorbed purified water 
in 12.0 ± 3.0 s, preparation C absorbed purified water in 17.1 ± 1.6s, 
preparation D absorbed purified water in 12.1 ± 3.1 s, and preparation E 
absorbed purified water in 52.8 ± 2.8s. Preparations B and D took nearly 
the same time to absorb water in (Figure 3), while preparations A, C, and 
E took significantly longer times. ODTs typically disintegrate by one of the 
following four mechanisms: 1) Moisture enters the tablet even if a small 
amount of saliva is present, and the whole tablet abruptly disintegrates. 
2) When a sufficient amount of water is present, the surface of the tablet 
gradually disintegrates as the tablet absorbs water, and moisture enters 
until it reaches the core of the tablet. Then, the core abruptly disintegrates. 
3) The surface of the tablet becomes pliable. Disintegration of the tablet 
is initially delayed, but once moisture reaches the core of the tablet, it 
abruptly disintegrates. 4) The entire tablet gradually disintegrates from its 
surface to its core at the same speed. These mechanisms of disintegration 
presumably lead to differences in water absorption rates. Preparations A 
and E gradually absorbed water starting at the surface of the tablet, where 
a thick layer of solution was formed, hampering the entry of water to 
the center of the tablet, while preparations B, C, and D allowed water to 
OD-tablets A B C D E
Appearance of formulations
Diameter* (mm) 6.52 ± 0.02 6.59 ± 0.03 7.13 ± 0.03 6.58 ± 0.01 6.57 ± 0.04
Thickness* (mm) 2.65 ± 0.25 2.74 ± 0.01 3.42 ± 0.02 2.75 ± 0.02 2.57 ± 0.02
Weight* (mg) 90.3 ± 0.5 96.1 ± 0.5 137.1 ± 0.5 96.1 ± 0.5 90.6 ± 0.7
Zolpidem tartrate content (%) 103.3 ± 2.7 102.9 ± 2.0 101.7 ± 3.1 103.9 ± 0.9 102.3 ± 1.6
Acceptance value 9.7 7.8 9.0 6.1 6.1
Table 2: Shape, weight, and content uniformity of ODTs
*Each value represents the mean ± S.D. (n=10).
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Figure 1: Dissolution rate-time profiles of zolpidem tartrate ODTs
Each point represents the mean ± S.D. (n=3)
Symbols are represented as follows; A: ○, B: △, C: ◆, D: ×, E: □.
Tukey test was performed for official approval (p<0.05).
*Significant differences were observed between A and C, B and C, and 
C and D, after 5 and 10min (p<0.05 for each). No differences were 
observed between A and B, A and D, A and E, B and D, B and E, C and 
E, or D and E. 
**Significant differences were observed between A and C, A and E, B 
and C, B and E, C and D, and D and E after 30min (p<0.05 for each). 
No differences were observed between A and B, A and D, B and D, or 
C and E.
Figure 3-1: Water absorption of Zolpidem tartrate OD-tablets
Tukey test was given to official approval (p<0.05).
*Significant differences were seen between A and B, A and C, A and D, 
A and E (p<0.05 for each). 
**Significant differences were seen between B and C, B and E (p<0.05 
for each).
***Significant differences were seen between C and D, C and E (p<0.05 
for each).
****Significant differences were seen between D and E (p<0.05 for 
each). 
Figure 2: Dissolution rate-time profiles of zolpidem tartrate ODTs in 
artificial saliva
Each point represents the mean ± S.D. (n=3)
Symbols are represented as follows; A: ○, B: △, C: ◆, D: ×, E: □.
Tukey test was performed for official approval (p<0.05).
*Significant differences were observed between A and C, A and E, B 
and C, B and D, B and E, C and D, and C and E after 10min (p<0.05 
for each). No differences were observed between A and B, A and D, or 
D and E.
**Significant differences were observed between A and C, B and 
C, C and D, and C and E after 15 and 30 min (p<0.05 for each). No 
differences were observed between A and B, A and D, A and E, B and 
D, B and E, or D and E.
pass through the surface of their tablets. Preparations A and E contain 
the binder HPC, which is a cellulose derivative in which hydroxyl groups 
have been substituted by hydroxylpropyl groups. HPC readily dissolves 
in water. However, preparations B and D contain L-HPC, which has 
fewer hydroxypropyl groups and is thus less water-soluble than HPC. 
This explains why water absorption by these preparations differed. When 
examining water absorption by an ODT, the test solution used should 
be similar to saliva in order to mimic the buccal environment. Thus, a 
water absorption test using artificial saliva was conducted. The test results 
showed that preparation A absorbed water in 34.0 ± 3.1 s, preparation B 
absorbed water in 8.8 ± 1.1 s, preparation C absorbed water in 16.6 ± 1.7s, 
preparation D absorbed water in 7.5 ± 0.9 s, and preparation E absorbed 
water in 46.1 ± 3.9 s. Preparations A, B, D, and E absorbed moisture from 
artificial saliva in a shorter time than they did from purified water. Only 
preparation C took nearly the same time to absorb water and moisture 
from saliva. HPC is a nonionic additive that is exceptionally compatible 
with different salts and drugs, so a preparation containing HPC will 
presumably absorb moisture from artificial saliva faster than purified 
water. Based on the previous results, we can conclude that preparations 
A and E disintegrate as follows: The tablet absorbs water, swells, and then 
disintegrates, while preparations B, C, and D have a porous structure, so 
they absorb water via capillarity and then disintegrate. 
Hardness test
Not only do tablet additives affect its water absorption rate, but also 
does its hardness. Thus, each preparation was subjected to a hardness test 
(Figure 4). Results of the hardness test showed that preparation A had 
a hardness of 30.6 ± 2.8 N, preparation B had a hardness of 34.3 ± 1.8 
N, preparation C had a hardness of 43.7 ± 2.4 N, preparation D had a 
hardness of 30.8 ± 1.2 N, and preparation E had a hardness of 41.7 ± 2.0 
N. On average, all preparations had a hardness of at least 30 N. Typically, a 
hardness level of 30 N or greater means that a tablet can tolerate an impact 
during the manufacturing process or transport [17], which means that 
the preparations had appropriate hardness. Preparations C and E were 
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ODTs [18]. The hardness test showed that preparation E is hard, which 
hampers water from entering the tablet, and the water absorption test 
showed that a thick layer of solution is formed on the tablet surface, 
which delays its disintegration. Like preparation E, preparation A also 
contains HPC, but preparation A is softer, which allows the water to enter 
the tablet more easily. In addition, HPC allowed the tablet to disintegrate 
before a thick layer of solution is formed. Although preparation C is hard, 
it disintegrated in a short time. Preparation C contained some additives 
that were not found in the other preparations, for example, it contained 
talc, colloidal silicon dioxide, and magnesium stearate as lubricants. These 
three lubricants are presumably the reasons why preparation C took less 
time to disintegrate despite its hardness. It disintegrated when water 
entered the tablet, but its ingredients delayed dissolution (Table 3). 
Conclusion
In this study, five different formulations of ZLP ODTs were subjected 
to a water absorption test, a hardness test, and a disintegration test. Our 
results indicate that the five preparations have different mechanisms of 
disintegration; preparations A and E gradually disintegrated at a constant 
speed starting from the surface of the tablet, preparations B and D 
rapidly disintegrated from the inside once water entered the tablet, and 
preparation C disintegrated once moisture reached the core of the tablet.
significantly harder than the other preparations. Given this finding, the 
hardness of preparation C presumably played a role in its low extent of 
dissolution within 5 min. Even though preparations A and E contained 
the same additive, their hardness levels differed. This could be the result 
of differences in the amount of the additive or in the tableting procedures 
(method of formulation).
Disintegration test
Upon administration, ODTs disintegrate in the mouth. A disintegration 
test was conducted in order to determine the extent to which water 
absorption and hardness affected tablet disintegration. Results of the 
disintegration test showed that preparation A disintegrated in 24.6 ± 1.9 s, 
preparation B disintegrated in 29.7 ± 2.0 s, preparation C disintegrated in 
22.6 ± 1.2 s, preparation D disintegrated in 23.0 ± 2.9 s, and preparation 
E disintegrated in 42.4 ± 2.0 s (Figure 4). Preparations A, B, C, and D 
took around 25s to disintegrate, while preparation E took 42s, i.e., it took 
significantly longer time than other preparations to disintegrate. The 
US Pharmacopeia (USP) recommends a disintegration time of 30 s for 
Figure 3-2: Artificial saliva absorption of Zolpidem tartrate OD-tablets
Tukey test was given to official approval (p<0.05).
*Significant differences were seen between A and B, A and C, A and D, 
A and E (p<0.05 for each). 
**Significant differences were seen between B and C, B and E (p<0.05 
for each).
***Significant differences were seen between C and D, C and E (p<0.05 
for each).
****Significant differences were seen between D and E (p<0.05 for each)
Figure 4: Correlation between hardness and disintegration time
Hardness: ■, Disintegration time: ○
OD-tablets A B C D E
Wetting time* (s)
Water 45.8 ± 4.7 12.0 ± 3.0 17.1 ± 1.6 12.1 ± 3.1 52.8 ± 2.8
Artificial saliva 34.0 ± 3.1 8.8 ± 1.1 16.6 ± 1.7 7.5 ± 0.9 46.1 ± 3.9
Hardness** (N) 30.6 ± 2.8 34.3 ± 1.8 43.7 ± 2.4 30.8 ± 1.2 46.1 ± 2.0
Disintegration time*** (s) 24.6 ± 1.9 29.7 ± 2.0 22.6 ± 1.2 23.0 ± 2.9 42.4 ± 2.0
Table 3: Wetting time, hardness, and disintegration time of ODTs.
*Each value represents the mean ± S.D. (n=10). Tukey test was performed for official approval (p<0.05). Significant differences were observed between A 
and B, A and C, A and D, A and E, B and C, B and E, C and D, C and E, and D and E. (p<0.05 for each). No differences were observed between B and D. 
**Each value represents the mean ± S.D. (n=11). Tukey test was performed for official approval (p<0.05). Significant differences were observed between A 
and B, A and C, A and E, B and C, B and D, B and E, C and D, and D and E. (p<0.05 for each). No differences were observed between A and D or C and D.
***Each value represents the mean ± S.D. (n=11). Tukey test was performed for official approval (p<0.05). Significant differences were observed 
between A and B, A and E, B and C, B and D, B and E, C and E, and D and E. (p<0.05 for each). No differences were observed between A and C, A and 
D, or C and D.
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Our results showed that preparations A, B, C, and D disintegrated 
within about 30 s. Thus, these preparations could be taken without 
water at bedtime and they will facilitate sleep without discomfort. In 
addition, they are beneficial for patients suffering from dysphagia, 
who are susceptible to choking when taking medications with water. 
In conclusion, those four preparations are convenient and simple to 
use. In contrast, preparation E took 42 s to disintegrate, and this long 
time could cause patients to feel discomfort. The current results were 
obtained by examining tablets from a single lot; therefore, other lots 
need to be examined as well. A pharmacist needs to talk to a patient 
face-to-face and ascertain a patient’s status in order to recommend him 
a generic that meets his needs. In the future, when pharmacists provide 
information to patients, they should be responsible for recommending the 
suitable medication in light of the patient’s adherence and compliance. 
Taking this into consideration, pharmacists need to have a basic 
understanding of the pharmaceutical properties of medications and they 
need to update their information on regular basis to be able to provide 
patients with better medical care.
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